Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
Read original at benzingaStocks · News reference
8-K filing — OptimizeRx Corp (OPRX)
Filed: 2026-08-12 AccNo: 0001448431-26-000014 Size: 815 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 12, 2026, 8:07 PM
- Checked
- Aug 12, 2026, 8:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est
OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
Read original at benzingaOptimizeRx Announces Appointment Of Andy D'Silva As CFO Effective January 1, 2027
Read original at benzingaOptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24 per share from the
Read original at benzinga